In direct compression campaigns for tigulixostat tablets, API lot characterization begins with laser diffraction under USP <429> and powder flow evaluation by USP <1174>. Particle size D50 values below 20 µm generally improve blend homogeneity but reduce flow, while D50 values above 75 µm may segregate from fine excipients in low-dose strengths. The API is pre-blended with microcrystalline cellulose NF and lactose monohydrate in a bin blender at 10 rpm for 20 minutes; croscarmellose sodium and colloidal silicon dioxide are added before final lubrication with 0.5% w/w sodium stearyl fumarate. Magnesium stearate at or below 0.5% w/w is used only after dissolution screening because hydrophobic lubrication films on tigulixostat particles can delay release. Compression on a Fette 2090i or Korsch XL 400 rotary press with B-tooling requires main compression force between 8 kN and 18 kN, turret speed of 30–60 rpm, and feed frame paddle speed below 30 rpm to limit particle attrition. Ejection force and residual radial die-wall force are monitored; ejection forces above 1.5 kN after lubrication suggest inadequate die wall binding prevention and raise the risk of picking or chipping.

Tablet critical quality attributes include content uniformity by USP <905> with acceptance value ≤ 15.0, disintegration by USP <701>, and dissolution by USP <711> Apparatus II with release specifications established under ICH Q6A. Direct compression is limited to formulations with Carr’s index below 25% and Hausner ratio below 1.25; published flow data for tigulixostat are limited, so pilot batches with 0.5–1.0% w/w colloidal silicon dioxide are evaluated before scale-up. Capping or lamination at compression force above 18 kN indicates insufficient plastic deformation and requires reformulation rather than force escalation. Tablets are packaged in PVC/PVDC/aluminum blisters with desiccant; storage conditions follow ICH Q1A(R2) at 25°C/60% RH and 40°C/75% RH. If the API contains residual solvents above ICH Q3C options, the blend is not released before gas chromatography under USP <467> confirms compliance.

What Limits Fill Weight Uniformity in Low-Dose Tigulixostat Capsule Operations?

Fill weight variation on a dosator-type capsule filling machine is controlled by powder column height inside the dosator bore, bulk density changes in the hopper, and vacuum profile during slug ejection. Cohesive tigulixostat lots with angle of repose above 40° or compressibility above 25% cannot be filled directly without a prior granulation step. A tamping pin machine with 3–5 tamping stations and 0.4–0.6 mm pin diameters is preferred for low-dose capsules because controlled compression of the powder bed reduces air entrapment and stabilizes fill weight. The fill weight target for a low-dose tigulixostat capsule is typically tighter than nominal ± 5%; check weighers integrated with the encapsulation unit provide automatic rejection of underfilled and overfilled capsules. Excipients that improve flow include pregelatinized starch and mannitol, while 0.25–0.5% w/w magnesium stearate is blended for 3–5 minutes after the API-excipient pre-blend to limit over-lubrication.

The capsule shell choice between hard gelatin and HPMC affects dissolution because HPMC capsules can rupture later in acidic media. Dissolution testing is performed by USP <711> Apparatus II with enzyme-free 0.1 N hydrochloric acid or pH 6.8 phosphate buffer according to the release specification. Empty capsule weight variation is controlled below 2% relative standard deviation to avoid masking API content uniformity failures. Production machines running at 60,000–120,000 capsules per hour can fluidize low-density filler blends and increase fill weight variation; therefore speed is reduced when the API fraction is below 5 mg per unit. Direct capsule filling is generally not feasible at very low tigulixostat content because segregation in the hopper creates super-potent and sub-potent units; wet or dry granulation is inserted before encapsulation. Blend uniformity is verified by stratified sampling across at least 10 locations in a V-blender or bin blender before the granulation transfer.

Wet Granulation Endpoint Control at Scale for Tigulixostat Tablets

Wet granulation becomes necessary when direct compression blends containing tigulixostat show flow function coefficients below 4 or segregation during scale-up. In a 300 L high-shear granulator such as a GEA Aeromatic-Fielder, the API and fillers are premixed for 5–10 minutes at impeller speed 100–150 rpm. Aqueous binder solution of povidone K30 or hydroxypropyl cellulose is sprayed at 5–15 kg/min with the chopper set to 1500–2500 rpm. Granule endpoint is monitored by impeller power draw and torque; a rapid power increase of 15–25% above dry mix baseline often corresponds to granule formation but not full densification. The wet mass is milled through a 2.0–4.0 mm screen and transferred to a fluid bed dryer. Inlet air temperature is maintained between 60°C and 75°C until loss on drying by USP <731> reaches 1.0–2.0% w/w. Dried granules are milled through a 0.8–1.2 mm conical screen; the target granule D50 is often 150–350 µm.

Over-wetting creates hard granules and raises compression force to reach acceptable hardness, while under-wetting creates weak granules that generate fines and cause capping. For tigulixostat, published data on granulation-induced polymorph transitions are limited; therefore milled granules are compared with the starting API by X-ray powder diffraction per USP <941> before final blending. Dissolution lag caused by excessive binder is prevented by limiting povidone concentration to 2–5% of final tablet weight. Granule blends are lubricated with 0.5% w/w magnesium stearate and compressed with pre-compression force set to 3–5 kN to remove entrapped air. Batch-to-batch variation is influenced by API particle size and binder addition rate; at 300 L scale, nozzle pressure of 1.0–2.0 bar and binder temperature of 20–25°C minimize variability. If tablet hardness falls below 50 N, disintegration may remain acceptable but friability may exceed 1.0% per USP <1216>; if hardness exceeds 100 N, dissolution may slow because of reduced porosity.

Dry granulation via roller compaction is evaluated for tigulixostat when the API is moisture-sensitive or when wet granulation changes crystallinity. The API is blended with microcrystalline cellulose, lactose, crospovidone, and magnesium stearate prior to compaction. Roller compaction parameters include roll pressure 30–80 bar, roll gap 1.5–3.0 mm, roll speed 5–12 rpm, and granulation screen size 0.8–1.5 mm. Ribbons with excessive hardness above 15 kp measured by a tablet hardness tester are discarded or remilled. Roller compaction reduces segregation and improves flow for low-dose tigulixostat capsules; however, loss of compactibility is a known failure mode if the API is over-dried or if the fine fraction below 75 µm is removed too aggressively. For tigulixostat, published data on compactibility and particle size after dry granulation are limited; therefore the granules must be tested for content uniformity per USP <905> and dissolution per USP <711> after each milling run. Dry granulated tigulixostat material is also suitable for encapsulation when wet binder contact must be avoided.

When Injectable Tigulixostat Requires Lyophilization Instead of Terminal Sterilization

For tigulixostat parenteral products, the primary manufacturing decision is whether the active substance can withstand terminal steam sterilization. If forced degradation studies under ICH Q1A(R2) and ICH Q1B demonstrate no impurity increase greater than the ICH Q3B reporting threshold and no chiral inversion, terminal sterilization at 121°C for 15 minutes may be used. If not, lyophilization is required. The lyophilization route begins with dissolution of tigulixostat in Water for Injection USP. pH is adjusted with 0.1 N hydrochloric acid or sodium hydroxide, and mannitol or trehalose is added as a bulking agent at 4–10% w/v. The solution is filtered through a 0.22 µm sterilizing grade membrane and filled into 2R, 6R, or 10R molded glass vials. Freezing is conducted at shelf temperatures between -40°C and -50°C; annealing may be introduced if the formulation shows incomplete crystallization of mannitol. Primary drying is controlled by the collapse temperature of the formulation measured by freeze-drying microscopy; if the collapse temperature is below -30°C, shelf temperature must be lowered to maintain product temperature below the collapse threshold. Typical primary drying pressures are 50–150 mTorr with shelf temperatures from -20°C to -10°C. Secondary drying at 25–40°C for 4–8 hours reduces residual moisture to 1.0% or less by Karl Fischer titration per USP <921>. Cake appearance is inspected for collapse, shrinkage, or melt-back; affected units are rejected because reconstitution time and potency may change.

The lyophilized cake is sealed with an elastomeric stopper and aluminum seal. Container closure integrity is tested by dye ingress or vacuum decay per USP <1207>; a validated leak rate of 6 × 10⁻⁶ mbar·L/s is a typical acceptance criterion for vial integrity. Subvisible particles are controlled by USP <787>, with not more than 6000 particles ≥ 10 µm and not more than 600 particles ≥ 25 µm per container. Sterility testing is performed per USP <71> and bacterial endotoxin testing per USP <85>. If reconstitution time exceeds 2 minutes or if the solution is hazy after reconstitution, the formulation requires additional surfactant or pH adjustment. Published stability data for lyophilized tigulixostat injection are limited; therefore the design space is established via small-scale freeze-drying trials with thermal characterization and mass spectrometry leak testing.

Ready-to-use injectable tigulixostat solutions require a stable aqueous formulation that can be aseptically filled or terminally sterilized. If terminal sterilization is selected, the solution is filled into vials under nitrogen to reduce oxidative degradation, and autoclave cycles are designed to achieve a minimum F₀ of 8 minutes at 121°C. Phosphate buffers may be used, but their concentration must not exceed 50 mM to avoid precipitation of divalent cations from glass; chelating agents such as disodium edetate are limited by stoichiometric compatibility with the API. The pH is generally maintained between 7.0 and 8.5 to balance solubility and chemical stability, but tigulixostat-specific pH stability data are not available in public literature, so the pH range is confirmed by accelerated degradation studies. For ready-to-use presentations, visible particles, subvisible particles, sterility, and endotoxin are tested as for lyophilized products. The choice between aseptic filling and terminal sterilization depends on the thermal degradation profile; if the API degrades by more than 1.0% total impurities at 121°C for 15 minutes, aseptic filtration is used instead. Aseptic filling requires a grade A environment with ISO 5 air, a 0.22 µm sterilizing filter, and a media fill process simulation success rate no less than 5000 units.

Granules containing tigulixostat are prepared for oral administration in sachets or unit-dose containers when tablets and capsules are not suitable. The granule intermediate from wet or dry granulation is screened to a particle size range of 200–500 µm and mixed with sweeteners, flavoring agents, and anti-caking agents. Loss on drying by USP <731> is controlled at 1.0–2.0% because excessive moisture causes sticking in high-speed sachet filling. Fill weight per sachet is controlled to ± 5% of target, and content uniformity follows USP <905>. The granules are packaged in aluminum foil sachets with a moisture barrier; if the API is sensitive to light, the sachet material includes an opaque layer. Dissolution of granules is tested by USP <711> Apparatus II with paddle speed 50 rpm and pH conditions matching the intended dosing vehicle. Reconstitution in water or fruit juice is only acceptable if the excipients are compatible and the API remains stable for 2 hours at room temperature. Published data on tigulixostat granule stability in suspension are limited; therefore stability in the reconstitution vehicle is tested at 25°C over 24 hours before use in clinical or commercial dosing scenarios.